Tag: MGTA-117
Magenta Therapeutics Halts Phase 1/2 Dose Escalation Trial of Conditioning ADC...
Magenta Therapeutics Halts Phase 1/2 Dose Escalation Trial of Conditioning ADC MGTA-117
Early Clinical Observations from MGTA-117 in Clinical Trial
Hematopoietic stem-cell transplantation, also known as a bone marrow transplant, includes the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral...
Magenta Therapeutics Confirms IND Clearance for MGTA-117; Expects to Open Phase...
Boston-based Magenta Therapeutics confirmed that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for MGTA-117 in Acute...
Preclinical Data from Magenta’s CD45-ADC Demonstrates Successful Immune Reset to Halt...
Data presented during the 46th annual (virtual) meeting of the European Society for Blood and Marrow Transplantation (EBMT), held August 29 to September 1,...
How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads...
Antibody-drug Conjugates or ADCs combine the selectivity of antibodies with the efficacy of small molecule drugs, allowing for more precise, targeted, therapeutic applications.
Combining the...
